Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial
about
Clopidogrel: an updated and comprehensive reviewManagement standards for stable coronary artery disease in India.Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.Risk of bleeding and repeated bleeding events in prasugrel-treated patients: a review of data from the Japanese PRASFIT studies.Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisNear-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapyMyocardial infarction in the elderlyNovel antiplatelet agent use for acute coronary syndrome in the emergency department: a reviewComparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trialHemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures.Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group.Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry.Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.Prasugrel: a critical comparison with clopidogrel.Pharmacogenetics guided anticoagulation.Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.Age related issues in reperfusion of myocardial infarction.Thrombin generation in hemorrhage control and vascular occlusion.Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?Subgroup analyses of clinical effectiveness to support health technology assessments.Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease.P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.Clinical pathways and management of antithrombotic therapy in patients with acute coronary syndrome (ACS): a Consensus Document from the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian Society of EReviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.Cangrelor for the management and prevention of arterial thrombosis.The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model.Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience.
P2860
Q28219411-87AA1EF7-D33A-441D-B6DC-764CF7185C67Q30239853-303EF750-EED1-4F05-BE5B-B17905E75508Q30569233-E3207304-CB85-4F43-83CA-1D08DADE3DAFQ31155185-7208CDB6-54D5-468A-9D68-45C0BCD8AA6FQ33561577-2D7876DB-4187-4362-9FA6-AD12CBD115BEQ34283146-4807925D-79C1-46C3-AEE4-EBA6EE9961DCQ34564576-6DF377D1-E47A-4F83-B8B7-532CE6ED2391Q35089550-FBABAB66-1861-40D2-A824-344C3F883ABAQ35373624-65690AC7-1024-4AC2-AF1D-B929C9A85DB4Q35806730-C1D89206-F3C7-4D45-AE56-9FE9F3EFE31AQ36676694-3CBE0403-8E3A-4F28-A4BD-578A15EA50C4Q36688145-CD11B511-F92F-4E6E-94D5-402BF9C26862Q36935879-DC8AEAAE-B907-412B-909E-607146ABCCB7Q36939417-C2528ACD-36A0-4189-9B45-FF991DB24C6BQ36941850-6A8FB99B-2D78-4914-BD91-279249FCB6AAQ37270473-D0CF68F8-AB7B-4935-87CE-75ADC58E9DF9Q37291860-32B5F106-BD74-4ACB-8BF5-0441BCC720F7Q37403998-51EB82AB-3FA8-473B-9459-91031BD6614AQ37445540-41E7D35B-562F-4121-8C0A-2F2DB09484E2Q37458916-827D5DFE-4172-4BCA-91D1-BDF8382571D7Q37641320-5D372F8B-7B17-491E-B7AD-75569316F7C1Q37808224-FB82D483-AEF4-474C-B8C8-8B0959F881D8Q37818331-4BC68383-0FBF-4035-B04C-BB467496D3E6Q37835616-6808556B-B819-454C-A80B-E5935DC9DB29Q37857757-D9B36E06-5E78-4242-8C00-B5B2652E2494Q37900072-E62A9D9D-F0B9-420F-8151-671FC19F8046Q37907902-DDA1148D-90FA-4BA4-9BBE-B7F67F3BDD05Q37964634-BA899056-C596-429C-B7DE-00D4D8EDD782Q37982427-B35A19AF-D15F-4B87-8BF5-2628D19EBC30Q38065738-F7A4960B-4A24-4630-8FB6-4FE843853187Q38151563-979E9D13-98EC-46E4-836A-72739A51AA2CQ38213705-F7ECD5FF-8E30-4B26-A2DC-C88F59962FE5Q38420789-3056986B-CFF0-44BD-908E-21D78E3541BFQ38656364-FB5A5F74-B04A-46AB-B182-87580B4857E1Q38765117-7B3FB6DC-9CC5-4D41-89AA-EC87E0AE8F58Q38846758-C6F5F20A-AA36-4FFB-A5B9-CA30E616532CQ39010701-137D203A-73D9-4322-9EA5-A13687C67F77Q40104177-AD0FCF9E-19A9-4B29-A661-E8E2FEA2D63FQ41016271-153872F9-01F8-49A6-AFC8-5F83D6C47E6CQ41025465-E7D54661-7ECB-4626-8CC0-DB73CD1D41AA
P2860
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial
description
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im Oktober 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: October 2006)
@en
vedecký článok (publikovaný 2006-10)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd in 2006-10)
@nl
наукова стаття, опублікована в жовтні 2006
@uk
مقالة علمية (نشرت في أكتوبر 2006)
@ar
name
Evaluation of prasugrel compar ...... rel Thrombolysis In Myocardial
@nl
type
label
Evaluation of prasugrel compar ...... rel Thrombolysis In Myocardial
@nl
prefLabel
Evaluation of prasugrel compar ...... rel Thrombolysis In Myocardial
@nl
P2093
P50
P921
P1476
Evaluation of prasugrel compar ...... Infarction 38 (TRITON-TIMI 38)
@en
P2093
C Michael Gibson
Carolyn H McCabe
Govinda Weerakkody
Jeffrey Riesmeyer
Jeffrey W Warmke
Kenneth J Winters
Stephen D Wiviott
P304
P356
10.1016/J.AHJ.2006.04.012
P407
P577
2006-10-01T00:00:00Z